CLPT Key Statistics, Chart & Performance
The current stock price of CLPT is 15.65 USD. In the past month the price increased by 20.66%. In the past year, price increased by 4.06%.
CLPT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.98 | 216.73B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.52 | 203.04B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.45 | 141.90B | ||
| SYK | STRYKER CORP | 27.44 | 138.20B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 57.48 | 57.87B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.3 | 48.17B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.93 | 39.58B | ||
| RMD | RESMED INC | 26.04 | 37.64B | ||
| DXCM | DEXCOM INC | 38.16 | 27.68B | ||
| PODD | INSULET CORP | 60.95 | 19.60B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.3 | 18.12B |
Related stock screener links
About CLPT
Company Profile
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 115 full-time employees. The company went IPO on 2019-07-03. The company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The company provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. The company also offers IRRAflow active fluid-exchange system.
Company Info
CLEARPOINT NEURO INC
120 S. Sierra Avenue, Suite 100
Solana Beach CALIFORNIA 92618 US
CEO: Joseph M. Burnett
Employees: 115
Phone: 19499006833
CLEARPOINT NEURO INC / CLPT FAQ
What does CLPT do?
Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The company is headquartered in Solana Beach, California and currently employs 115 full-time employees. The company went IPO on 2019-07-03. The company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. The company is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. The company provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. The company also offers IRRAflow active fluid-exchange system.
What is the stock price of CLEARPOINT NEURO INC today?
The current stock price of CLPT is 15.65 USD. The price increased by 4.89% in the last trading session.
Does CLPT stock pay dividends?
CLPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of CLPT stock?
CLPT has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is CLEARPOINT NEURO INC (CLPT) stock traded?
CLPT stock is listed on the Nasdaq exchange.
How is the market expecting CLPT stock to perform?
8 analysts have analysed CLPT and the average price target is 29.58 USD. This implies a price increase of 89.01% is expected in the next year compared to the current price of 15.65.
How is the valuation of CLEARPOINT NEURO INC (CLPT) based on its PE ratio?
CLEARPOINT NEURO INC (CLPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
CLPT Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CLPT. When comparing the yearly performance of all stocks, CLPT is a bad performer in the overall market: 84.42% of all stocks are doing better.
CLPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLPT. While CLPT seems to be doing ok healthwise, there are quite some concerns on its profitability.
CLPT Financial Highlights
Over the last trailing twelve months CLPT reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -21.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -38.34% | ||
| ROE | -145.77% | ||
| Debt/Equity | 1.84 |
CLPT Forecast & Estimates
8 analysts have analysed CLPT and the average price target is 29.58 USD. This implies a price increase of 89.01% is expected in the next year compared to the current price of 15.65.
For the next year, analysts expect an EPS growth of -20.94% and a revenue growth 14.96% for CLPT